Randomized Trial of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor in Pediatric Patients Receiving Intensive Myelosuppressive Chemotherapy

Journal of Clinical Oncology

Volumn 14, Issue 3, 1996, Pages 901-910

  Wexler, Leonard H ^a   Weaver McClure, Linda ^b   Steinberg, Seth M ^b   Jacobson, Joan ^b   Jarosinski, Paul ^b   Avila, Nilo ^b   Pizzo, Philip A ^b   Horowitz, Marc E ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ARTHRALGIA; ARTICLE; BONE MARROW SUPPRESSION; BONE PAIN; CANCER CHEMOTHERAPY; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEMALE; GRANULOCYTOPENIA; HEADACHE; HUMAN; INFECTION COMPLICATION; LUNG TOXICITY; MALAISE; MALE; MUCOSA INFLAMMATION; MYALGIA; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SARCOMA; SKIN TOXICITY; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGRANULOCYTOSIS; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HOSPITALIZATION; HUMANS; INFANT; INFECTION; MALE; PROSPECTIVE STUDIES; SARCOMA; THROMBOCYTOPENIA;

EID: 0029960016     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.3.901     Document Type: Article

References (37)

1. Burgert EO, Nesbit ME, Garnsey LA, et al: Multimodal therapy for the management of nonpelvic, localized Ewing's sarcoma of bone: Intergroup study IESS-II. J Clin Oncol 8:1514-1524, 1990
2. Smith MA, Ungerleider RS, Horowitz ME, et al: Influence of doxorubicin dose intensity on response and outcome for patients with osteogenic sarcoma and Ewing's sarcoma. J Natl Cancer Inst 83:1460-1470, 1991
3. Horowitz ME, Kinsella TJ, Wexler LH, et al: Total-body irradiation and autologous bone marrow transplant in the treatment of high-risk Ewing's sarcoma and rhabdomyosarcoma. J Clin Oncol 11:1911-1918, 1993
4. Freifeld AG, Hathorn JW, Pizzo PA: Infectious complications in the pediatric cancer patient, in Pizzo PA, Poplack DG (eds): Principles and Practice of Pediatric Oncology (ed 2). Philadelphia, PA, Lippincott, 1993, pp 987-1019
5. Laver J, Moore MAS: Clinical use of recombinant human hematopoietic growth factors. J Natl Cancer Inst 81:1370-1382, 1989
6. Groopman JE, Mitsuyasu RT, DeLeo MJ, et al: Effect of recombinant human granulocyte-macrophage colony-stimulating factor on myelopoiesis in the acquired immunodeficiency syndrome. N Engl J Med 317:593-598, 1987
7. Vadhan-Raj S, Keating M, LeMaistre A, et al: Effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. N Engl J Med 317:1545-1552, 1987
8. Brandt SJ, Peters WP, Atwater SK, et al: Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. N Engl J Med 318:869-876, 1988
9. Nemunaitis J, Singer JW, Buckner CD, et al: Use of recombinant human granulocyte-macrophage colony-stimulating factor in autologous marrow transplantation for lymphoid malignancies. Blood 72:834-836, 1988
10. Antman KS, Griffin JD, Elias A, et al: Effect of recombinant human granulocyte-macrophage colony stimulating factor on chemotherapy-induced myelosuppression. N Engl J Med 319:593-598, 1988
11. Hermann F, Schulz G, Lindemann A, et al: Hematopoietic responses in patients with advanced malignancy treated with recombinant human granulocyte-macrophage colony stimulating factor. J Clin Oncol 7:159-167, 1989
12. Nemunaitis J, Buckner CD, Applebaum FR, et al: Phase I/II trial of recombinant human granulocyte-macrophage colony-stimulating factor following allogeneic bone marrow transplantation. Blood 77:2065-2071, 1991
13. Nemunaitis J, Rabinowe SN, Singer JW, et al: Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N Engl J Med 324:1773-1778, 1991
14. Furman WL, Fairclough DL, Huhn RD, et al: Therapeutic effects and pharmacokinetics of recombinant human granulocyte-macrophage colony-stimulating factor in childhood cancer patients receiving myelosuppressive chemotherapy. J Clin Oncol 9:1022-1028, 1991
15. Nemunaitis J, Anasetti C, Storb R, et al: Phase II trial of recombinant human granulocyte-macrophage colony-stimulating factor in patients undergoing allogeneic bone marrow transplantation from unrelated donors. Blood 79:2572-2577, 1992
16. Hovgaard D, Nissen NI: A phase I/II study of dose and administration of non-glycosylated bacterially synthesized G-M CSF in chemotherapy-induced neutropenia in patients with non-Hodgkin's lymphoma. Leuk Lymphoma 7:217-224, 1992
17. Neidhart JA, Mangalik A, Stidley CA, et al: Dosing regimen of granulocyte-macrophage colony-stimulating factor to support dose-intensive chemotherapy. J Clin Oncol 10:1460-1469, 1992
18. Edmonson JH, Hartman LC, Long HJ, et al: Granulocyte-macrophage colony-stimulating factor: Preliminary observations on the influence of dose, schedule, and route of administration in patients receiving cyclophosphamide and carboplatin. Cancer 70:2529-2539, 1992
19. Saarinen UM, Hovi L, Riikonen P, et al: Recombinant human granulocyte-macrophage colony-stimulating factor in children with chemotherapy-induced neutropenia. Med Pediatr Oncol 20:489-496, 1992
20. Steward WP, Verweij J, Somers R, et al: Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: A study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 11:15-21, 1993
21. Aglietta M, Monzeglio C, Pasquino P, et al: Short-term administration of granulocyte-macrophage colony stimulating factor decreases hematopoietic toxicity of cytostatic drugs. Cancer 72:2970-2973, 1993
22. de Vries EGE, Biesma B, Willemse PHB, et al: A double-blind placebo-controlled study with granulocyte-macrophage colony-stimulating factor during chemotherapy for ovarian carcinoma. Ca Res 51:116-122, 1991
23. Gurney H, Anderson H, Radford J, et al: Infection risk in patients with small cell lung cancer receiving intensive chemotherapy and recombinant granulocyte-macrophage colony-stimulating factor. Eur J Cancer 28:105-112, 1992
24. Gerhartz HH, Engelhard M, Meusers P, et al: Randomized, double-blind, placebo-controlled, phase III study of recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to induction treatment of high-grade malignant non-Hodgkin's lymphomas. Blood 82:2329-2339, 1993
25. Ardizzoni A, Venturini M, Sertoli MR, et al: Granulocyte-macrophage colony-stimulating factor (GM-CSF) allows acceleration and dose intensity increase of CEF chemotherapy: A randomised study in patients with advanced breast cancer. Br J Cancer 69:385-391, 1994
26. Shaffer DW, Smith LS, Burris HA, et al: A randomized phase I trial of chronic oral etoposide with or without granulocyte-macrophage colony-stimulating factor in patients with advanced malignancies. Ca Res 53:5929-5933, 1993
27. Hermann F, Schulz G, Wieser M, et al: Effect of granulocyte-macrophage colony-stimulating factor on neutropenia and related morbidity induced by myelotoxic chemotherapy. Am J Med 88:619-624, 1990
28. Marina N, Shema SJ, Bowman LC, et al: Failure of granulocyte-macrophage colony-stimulating factor to reduce febrile neutropenia in children with recurrent solid tumors treated with ifosfamide, carboplatin, and etoposide chemotherapy. Med Pediatr Oncol 23:328-334, 1994
29. Rabinowe SR, Neuberg D, Bierman PH, et al: Long-term follow-up of a phase III study of recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid malignancies. Blood 81:1903-1908, 1993
30. Ozer H: American Society of Clinical Oncology recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines. J Clin Oncol 12:2471-2508, 1994
31. Ellis RE: The distribution of active bone marrow in the adult. Phys Med Biol 5:255-258, 1961
32. Atkinson HR: Bone marrow distribution as a factor in estimating radiation to the blood-forming organ: A survey of present knowledge. J Coll Radiol Aust 6:149-154, 1962
33. Iglehart JK: The struggle between managed care and fee-for-service practice. N Engl J Med 331:63-67, 1994
34. Kassirer JP, Angell M: The journal's policy on cost-effectiveness analyses. N Engl J Med 331:669-670, 1994 (editorial)
35. Lyman GH, Lyman CH, Sanderson RA, et al: Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy. J Natl Cancer Inst 85:488-493, 1993
36. Canellos GP: Myelosuppression and "conventional" chemotherapy: What price, what benefit? J Clin Oncol 11:1-2, 1993 (editorial)
37. Demetri GD: Beyond supportive care: What are the next questions in the use of hematopoietic cytokines with cytotoxic chemotherapy? Blood 82:2278-2280, 1993 (editorial)